vilobelimab + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
Nov 1, 2023 → Jul 11, 2025
NCT ID
NCT05964413About vilobelimab + Placebo
vilobelimab + Placebo is a phase 3 stage product being developed by InflaRx for Pyoderma Gangrenosum. The current trial status is terminated. This product is registered under clinical trial identifier NCT05964413. Target conditions include Pyoderma Gangrenosum.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05964413 | Phase 3 | Terminated |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| sisomicin | Merck | Approved | 85 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 52 |
| Secukinumab | Novartis | Phase 1/2 | 41 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 32 |
| gevokizumab | XOMA | Phase 2 | 44 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| gevokizumab | XOMA | Phase 3 | 69 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| vilobelimab | InflaRx | Phase 2 | 44 |
Other Products from InflaRx
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOCPhase 2/3
57
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)Phase 2
44
Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + PlaceboPhase 2
44